(lp0
S'AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial Business Wire  - Mar 14, 2017 MASON, Ohio----AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation  and left atrial appendage management, today announced that it has named Dr.'
p1
aS"BTIG Downgrades AtriCure Inc.  to Neutral StreetInsider.com - Mar 6, 2017 BTIG downgraded AtriCure Inc.  from Buy to Neutral. Analyst Dr. Sea Lavin comments &quot;We followed up with ATRC's management team following the company's earnings report at our Snowbird conference.AtriCure Inc.  Plunges 6.01% on March 06 - Equities.comAtriCure Announces hiring of Senior Vice President of Clinical, Regulatory ... - Yahoo Finance"
p2
aS'AtriCure Inc.  Given Average Recommendation of Buy by Brokerages The Cerbat Gem - 13 hours ago AtriCure logo Shares of AtriCure Inc.  have been assigned an average rating of Buy from the nine ratings firms that are currently covering the stock.AtriCure, Inc.  Target Price At $24 - Markets DailyNorthland Securities Releases a Buy Rating on Atricure - Analyst Ratings'
p3
aS'AtriCure - Management Needs To Find A Cure For Continued Losses Seeking Alpha - Jan 18, 2017 AtriCure is a great growth story but losses, and the resultant dilution, limit growth for investors. Despite solid growth prospects going forwards, investors are anticipating further dilution as well as profits are not yet in sight.'
p4
aS'Stock Alert: AtriCure Inc Price Volatility Hits A Depressed Level CML News - Mar 19, 2017 Before we cover the full analysis we make a quick alert here that AtriCure Inc  has seen its stock price move at a substantially lowered level.'
p5
aS"Stock to Track: AtriCure, Inc.  Is stories - 16 hours ago AtriCure, Inc.'s  witnessed a gain of 0.48% in recent trading period with closing price of $ 18.96. The company's last traded volume of 0.29 million shares as compared to it's an average volume of 0.26 million shares."
p6
aS'AtriCure, Inc. : Is The Stock Undervalued? Business Review - Mar 17, 2017 The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.'
p7
aS'Stock slips as AtriCure acquires competitor for $149M Cincinnati Business Courier - Oct 5, 2015 Stock in AtriCure Inc. dropped nearly 11 percent today on news that the West Chester company has agreed to acquire a North Carolina-based competitor, nContact Inc., for up to $149 million.AtriCure Enters Into Definitive Agreement to Acquire nContact - Business Wire AtriCure to Buy Heart Device Developer nContact for $99M - Xconomy'
p8
aS'AtriCure Enrolls First Patient in Randomized Multi-Center Trial Evaluating ... Business Wire  - Feb 17, 2016 WEST CHESTER, Ohio----AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation  and left atrial appendage management, announced today that the first patient was enrolled and treated at PinnacleHealth&nbsp;...'
p9
aS'Stock Returns: AtriCure Inc  versus CryoLife Inc  CML News - Mar 14, 2017 This is a snapshot to compare the stock returns for AtriCure Inc  versus CryoLife Inc  . The stock return points we compare look at the last three-months, six-months and twelve-months.'
p10
a.